T. Rowe Price Associates
LFMD icon

T. Rowe Price Associates’s LifeMD LFMD Stock Holding History

T. Rowe Price Associates’s Portfolio LFMD Stock Details LFMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Buy
28,579
+9,297
+48% +$32.2K ﹤0.01% 2994
2025
Q4 		$66K Hold
19,282
– – ﹤0.01% 3004
2025
Q3 		$131K Buy
19,282
+1,529
+9% +$12.6K ﹤0.01% 2877
2025
Q2 		$242K Buy
17,753
+1,470
+9% +$13.9K ﹤0.01% 2623
2025
Q1 		$89K Buy
16,283
+2,271
+16% +$12.9K ﹤0.01% 2845
2024
Q4 		$70K Buy
14,012
+2,895
+26% +$15.2K ﹤0.01% 2888
2024
Q3 		$59K Hold
11,117
– – ﹤0.01% 2908
2024
Q2 		$0 Buy
+11,117
New +$102K ﹤0.01% 2979
2022
Q3 		– Sell
-18,900
Closed -$39K – 3009
2022
Q2 		$39K Hold
18,900
– – ﹤0.01% 2886
2022
Q1 		$67K Hold
18,900
– – ﹤0.01% 2898
2021
Q4 		$73K Hold
18,900
– – ﹤0.01% 2905
2021
Q3 		$117K Sell
18,900
-6,100
-24% -$52K ﹤0.01% 2819
2021
Q2 		$295K Buy
+25,000
New +$288K ﹤0.01% 2604

Other funds holding LFMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates's LFMD Position: Q1 2026 in Review

T. Rowe Price Associates increased its LifeMD (LFMD) stake by 48% in Q1 2026, buying an estimated $32.2K and bringing the position to 28,579 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

T. Rowe Price Associates first reported a position in LFMD in Q2 2021 and has held it in 13 quarters since. The position peaked at $295K in Q2 2021. 102 funds tracked by Wall St. Rank hold LFMD as of Q1 2026.

  • T. Rowe Price Associates held 28,579 shares of LifeMD worth $104K as of Q1 2026.
  • T. Rowe Price Associates bought 9,297 LifeMD shares in Q1 2026, an estimated $32.2K.
  • LifeMD made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2994 holding.
  • T. Rowe Price Associates first reported a position in LifeMD in Q2 2021 and has held it in 13 quarters since.
  • T. Rowe Price Associates's LifeMD position peaked at $295K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held LifeMD as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.